American College of Gastroenterology: Upfront Biologics Improve Crohn’s Outcomes, State University of New York at Buffalo Study

MedPageToday -- SAN ANTONIO -- In a small study, adolescents diagnosed with Crohn’s disease who were treated in a “top-down” treatment scheme -- receiving potent biologic agents as a first-line therapy -- tended to have less surgery, less frequent hospitalization, and fewer complications than similar patients treated in “step-up” regimens.